Philippe Couttet is a Research Investigator, heading the Pathway Integration Lab, at the Novartis Institutes of Biomedical Research in Basel.

He studied Biochemistry at the University Pierre et Marie Curie in Paris. During his PhD, Philippe studied the mechanisms of mRNA degradation pathways in mammals (Institut Jacques Monod, CNRS, Paris). Then he did a short post-doc on bone disease sponsored by Aventis in Paris (INSERM, Paris) followed by another post-doc in the transcriptomic unit of GSK (Stevenage, UK) sponsored by a Marie Curie Fellowship. Philippe went back to academia and had a scientist position at the Wellcome Trust Sanger Institute (Cambridge, UK). Finally, he joined Novartis Pharma in 2006 in the Discovery and Investigative Safety unit.